Aminopyridines as protein kinase Cθ inhibitors

Abstract

There is a continued interest in pursuing protein kinase C (PKC)θ as a potential novel therapeutic target. A recently published patent application from Boeh- ringer Ingelheim discloses pyridine derivatives as PKCθ inhibitors, many of which possess inhibitory activity down to low nM. These compounds display selective inhibition profiles over other kinases.

Keywords::

• cytokine
• immunological disorder
• PKCθ inhibitor
• Type 2 diabetes

Patent Details

• Title Pyridine derivatives useful as inhibitors of PKCτ.

• Assignee Boehringer Ingelheim International GmbH.

• Inventors Brunette SR, Kim JM, Lemieux RM, Tschantz MA.

• Priority date 27/03/06.

• Filing date 27/03/06.

• Publication date 28/09/06.

• Publication no. US20060217417.